ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0506

Immunophenotypic Categorization of Systemic Immune-mediated Diseases

Shinji Izuka1, Toshihiko Komai1, Takahiro Itamiya1, Mineto Ota2, Saeko Yamada1, Yasuo Nagafuchi2, Hirofumi Shoda1, Kosuke Matsuki3, Kazuhiko Yamamoto4, Tomohisa Okamura2 and Keishi Fujio1, 1Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Bunkyo City, Tokyo, Japan, 2Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Department of Functional Genomics and Immunological Diseases, Graduate School of Medicine, The University of Tokyo, Bunkyo City, Tokyo, Japan, 3Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Japan, 4Laboratory for Autoimmune Diseases, Center for Integrative Medical Sciences, the Institute of Physical and Chemical Research (RIKEN), Wako, Saitama, Japan

Meeting: ACR Convergence 2022

Keywords: autoimmune diseases, B-Lymphocyte, Dendritic cells, immunology, T Cell

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 12, 2022

Title: Abstracts: Miscellaneous Rheumatic and Inflammatory Diseases I

Session Type: Abstract Session

Session Time: 3:00PM-4:30PM

Background/Purpose: Systemic immune-mediated diseases are heterogeneous, and the pathogenesis varies among and within each disease. Some studies tried to stratify patients with immune-mediated diseases into some subgroups by the data of molecular patter or mass spectrometry [1,2]; however, to date, classification of the disease generally is based on symptoms and some specific serological features, and the treatment is relatively uniform depending on the diagnosis and affected organs. We conducted this study to reveal what kinds of immune cells are involved in each disease and reclassify them with cell proportions.

Methods: Immunophenotyping of 258 patients with systemic immune-mediated diseases, including 21 mixed connective tissue disease (MCTD), 59 idiopathic inflammatory myopathy (IIM), 20 rheumatoid arthritis (RA), 87 systemic lupus erythematosus (SLE), 52 systemic sclerosis (SSc), and 19 Takayasu arteritis (TAK) were undertaken (Table 1). We collected the clinical data and sorted a total of 32 types of immune cells from PBMCs using flow cytometry. We selected 11 out of 32 disease-specific immune cells whose variances were more than 0.10 and compared the proportion of immune cells and clinical data in each population. Categorical and continuous variables were compared using the chi-square test and analysis of variance (ANOVA). A hierarchical clustering procedure by calculating Euclidean distance and using Ward’s method was performed to form clusters from the Z score of immune cell proportions.

Results: The hierarchical clustering of flow cytometry data of 11 immune cells, including CD8+ T, central memory CD8+ T, CD4+ T, naïve CD4+ T, follicular helper T (Tfh), switched memory B, unswitched memory B, classical monocytes, non-classical monocytes, myeloid dendritic cell (DC), and CD141+ myeloid DC identified 4 clusters (Table 2, Figure 1A). Cluster 1,2, and 4 were dominant SLE, SSc, and IIM, respectively (Figure 1B). Cluster 3 contained miscellaneous diseases but most TAK patients were classified into this group. Each cluster showed high proportions of CD8+ T in cluster 1, central memory CD8+ T, Tfh, non-classical monocytes in cluster 2, unswitched memory B, switched memory B, myeloid DC, and CD141+ myeloid DC in cluster 3, and CD4+ T, naïve CD4+ T, and classical monocytes in cluster 4.

Conclusion: The systemic immune-mediated diseases such as MCTD, IIM, RA, SLE, SSc, and TAK were classified into four groups by the immune cell proportions. Our data may corroborate the understanding of the pathogenesis of various systemic immune-mediated diseases and can be a clue to reclassifying them by the associated immune cells.

Supporting image 1

Table 1. Patients’ characteristics in each systemic immune-mediated disease.

Supporting image 2

Table 2. Cell populations of four clusters.

Supporting image 3

Figure 1. Heatmap of hierarchical clustering of 11 types of immune cells (A) and Proportion of disease in four clusters (B).


Disclosures: S. Izuka, None; T. Komai, Chugai Pharmaceutical.; T. Itamiya, None; M. Ota, Chugai Pharmaceutical.; S. Yamada, None; Y. Nagafuchi, Chugai Pharmaceutical.; H. Shoda, Chugai Pharmaceutical.; K. Matsuki, Chugai Pharmaceutical.; K. Yamamoto, None; T. Okamura, Chugai Pharmaceutical.; K. Fujio, Chugai Pharmaceutical..

To cite this abstract in AMA style:

Izuka S, Komai T, Itamiya T, Ota M, Yamada S, Nagafuchi Y, Shoda H, Matsuki K, Yamamoto K, Okamura T, Fujio K. Immunophenotypic Categorization of Systemic Immune-mediated Diseases [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/immunophenotypic-categorization-of-systemic-immune-mediated-diseases/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/immunophenotypic-categorization-of-systemic-immune-mediated-diseases/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology